Abstract
Oncotype DX is a 21-gene assay that quantifies the recurrence risk in estrogen receptorg-positive breast cancer, which is expressed as the recurrence score (RS). Studies have shown that patients with a high-risk RS will most likely benefit from adjuvant chemotherapy, but there is no proven advantage for patients with a low-risk RS who still face an average recurrence risk of 7%. In this study, the relationship between the RS and the cell cycleg-related antigen Ki-67 was assessed in 32 breast carcinomas and evaluated for a potential association. Comparison of the RS with tumor type, grade, and the Ki-67 proliferation index (PI) revealed an overall concordance. However, some tumors with a low RS revealed a surprisingly high Ki-67 PI. These cases may correspond to the 7% of low-risk RS carcinomas that recur. Therefore, the authors propose a combined evaluation of the RS and Ki-67 PI to identify tumors with high recurrence potential from the low-risk and intermediate-risk RS groups.
Original language | English (US) |
---|---|
Pages (from-to) | 303-310 |
Number of pages | 8 |
Journal | International Journal of Surgical Pathology |
Volume | 17 |
Issue number | 4 |
DOIs | |
State | Published - Aug 2009 |
Keywords
- Breast
- Carcinoma
- Ki-67
- Molecular profiling
- Oncotype DX
- Prognosis
- Recurrence score
ASJC Scopus subject areas
- Anatomy
- Surgery
- Pathology and Forensic Medicine